X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse GSK Pharma with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs MYLAN (US) - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 GSK PHARMA   MYLAN
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
MYLAN
Dec-14
GSK PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs3,8384,042-   
Low Rs2,6372,848-   
Sales per share (Unadj.) Rs354.21,383.8-  
Earnings per share (Unadj.) Rs39.8166.7-  
Cash flow per share (Unadj.) Rs42.9268.3-  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.9687.9-  
Shares outstanding (eoy) m84.70378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x9.12.5 367.1%   
Avg P/E ratio x81.420.7 393.9%  
P/CF ratio (eoy) x75.512.8 588.2%  
Price / Book Value ratio x13.75.0 272.8%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2161,303,581 21.0%   
No. of employees `0004.725.0 18.8%   
Total wages/salary Rs m4,8300-   
Avg. sales/employee Rs Th6,387.020,942.8 30.5%   
Avg. wages/employee Rs Th1,028.30-   
Avg. net profit/employee Rs Th717.12,522.9 28.4%   
INCOME DATA
Net Sales Rs m30,000523,570 5.7%  
Other income Rs m728-3,052 -23.9%   
Total revenues Rs m30,728520,519 5.9%   
Gross profit Rs m4,190130,214 3.2%  
Depreciation Rs m26338,454 0.7%   
Interest Rs m022,584 0.0%   
Profit before tax Rs m4,65566,125 7.0%   
Minority Interest Rs m0-271 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,7442,781 62.7%   
Profit after tax Rs m3,36863,073 5.3%  
Gross profit margin %14.024.9 56.2%  
Effective tax rate %37.54.2 890.9%   
Net profit margin %11.212.0 93.2%  
BALANCE SHEET DATA
Current assets Rs m16,742460,288 3.6%   
Current liabilities Rs m7,202359,853 2.0%   
Net working cap to sales %31.819.2 165.8%  
Current ratio x2.31.3 181.7%  
Inventory Days Days5278 66.4%  
Debtors Days Days21107 19.4%  
Net fixed assets Rs m8,635121,127 7.1%   
Share capital Rs m84718,515 4.6%   
"Free" reserves Rs m19,2220-   
Net worth Rs m20,069260,266 7.7%   
Long term debt Rs m10388,812 0.0%   
Total assets Rs m30,0381,048,328 2.9%  
Interest coverage xNM3.9-  
Debt to equity ratio x01.5 0.0%  
Sales to assets ratio x1.00.5 200.0%   
Return on assets %11.28.2 137.2%  
Return on equity %16.824.2 69.3%  
Return on capital %25.513.6 186.9%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m-6,6650-   
CASH FLOW
From Operations Rs m2,36068,824 3.4%  
From Investments Rs m3,008-54,276 -5.5%  
From Financial Activity Rs m-5,108-18,135 28.2%  
Net Cashflow Rs m260-3,588 -7.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 67.82 Rs / USD

Compare GSK PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare GSK PHARMA With: ALEMBIC PHARMA  UNICHEM LAB  PLETHICO PHARMA  AJANTA PHARMA  DISHMAN PHARMA  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views On News

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jun 22, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA 8-QTR ANALYSIS

COMPARE GSK PHARMA WITH

MARKET STATS